Search by Drug Name or NDC
NDC 00025-1720-03 Inspra 50 mg/1 Details
Inspra 50 mg/1
Inspra is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is EPLERENONE.
MedlinePlus Drug Summary
Eplerenone is used alone or in combination with other medications to treat high blood pressure. Eplerenone is in a class of medications called mineralocorticoid receptor antagonists. It works by blocking the action of aldosterone, a natural substance in the body that raises blood pressure. High blood pressure is a common condition and when not treated, can cause damage to the brain, heart, blood vessels, kidneys and other parts of the body. Damage to these organs may cause heart disease, a heart attack, heart failure, stroke, kidney failure, loss of vision, and other problems. In addition to taking medication, making lifestyle changes will also help to control your blood pressure. These changes include eating a diet that is low in fat and salt, maintaining a healthy weight, exercising at least 30 minutes most days, not smoking, and using alcohol in moderation.
Related Packages: 00025-1720-03Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Eplerenone
Product Information
| NDC | 00025-1720 |
|---|---|
| Product ID | 0025-1720_d9c94e3a-5db0-4cf4-be46-c9501930818b |
| Associated GPIs | 36250030000330 |
| GCN Sequence Number | 051037 |
| GCN Sequence Number Description | eplerenone TABLET 50 MG ORAL |
| HIC3 | R1H |
| HIC3 Description | POTASSIUM SPARING DIURETICS |
| GCN | 91884 |
| HICL Sequence Number | 024316 |
| HICL Sequence Number Description | EPLERENONE |
| Brand/Generic | Brand |
| Proprietary Name | Inspra |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | eplerenone |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 50 |
| Active Ingredient Units | mg/1 |
| Substance Name | EPLERENONE |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Pharmaceutical Class | Aldosterone Antagonist [EPC], Aldosterone Antagonists [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA021437 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00025-1720-03 (00025172003)
| NDC Package Code | 0025-1720-03 |
|---|---|
| Billing NDC | 00025172003 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE (0025-1720-03) |
| Marketing Start Date | 2002-09-27 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |